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Abstract
 
Some pathogens (e.g., 
 
Mycobacterium tuberculosis, Toxoplasma gondii, Leishmania spp
 
) have been
shown to persist in their host after clinical cure, establishing the risk of disease reactivation. We
analyzed the conditions necessary for the long term maintenance of 
 
Leishmania major
 
 in geneti-
cally resistant C57BL/6 mice after spontaneous healing of their dermal lesions. Interleukin
(IL)-10 was found to play an essential role in parasite persistence as sterile cure was achieved in
IL-10–deficient and IL-4/IL-10 double-deficient mice. The requirement for IL-10 in estab-
lishing latency associated with natural infection was confirmed in IL-10–deficient mice chal-
lenged by bite of infected sand flies. The host-parasite equilibrium was maintained by CD4
 
 
 
and CD8
 
 
 
 T cells which were each able to release IL-10 or interferon (IFN)-
 
 
 
, and were
found to accumulate in chronic sites of infection, including the skin and draining lymph node.
A high frequency of the dermal CD4
 
  
 
T cells released both IL-10 and IFN-
 
 
 
. Wild-type mice
treated transiently during the chronic phase with anti–IL-10 receptor antibodies achieved ster-
ile cure, suggesting a novel therapeutic approach to eliminate latency, infection reservoirs, and
the risk of reactivation disease.
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Introduction
 
The persistence of pathogens after clinical cure is a hall-
mark of certain viral, bacterial, and parasitic infections.
With respect to the various clinical forms of Leishmaniasis,
low numbers of viable organisms persist within lymphoid
tissue and/or the site of the former skin lesion after self-
cure or successful chemotherapy (1, 2). Such latent infec-
tions often give rise to severe forms of reactivation disease,
including visceral leishmaniasis (VL) associated with, for
example, HIV co-infection (3); the development of post-
kala-azar dermal leishmaniasis (PKDL) after cure of VL (4);
reactivation of former skin lesions, termed recidivans type
(5); and development of mucosal leishmaniasis months or
years after healing of a localized cutaneous ulcer (6). While
 
L. major
 
 infection in genetically resistant mice has been typ-
ically studied to define the mechanisms involved in ac-
quired resistance, the finding that sterile immunity is not
achieved in these mice has established the model as useful
for also defining the conditions favoring parasite persistence
and reactivation (7). Immune pressure during the chronic
phase is maintained by CD4
 
 
 
 T cells, IL-12, IFN-
 
 
 
, and
inducible nitric oxide synthase (iNOS),
 
* 
 
as impairment of
these responses during latency has been shown in each case
to promote parasite growth and the reappearance of lesions
(8–10). In contrast, the explanation as to why these control
mechanisms fail to completely eliminate the parasite is not
known; immunologic or genetic manipulations that can
disrupt the host-parasite equilibrium in favor of the host
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have not been described. Nonetheless, the observations
that dendritic cells (DCs) (11) and especially fibroblasts
(12), harbor low numbers of amastigotes during latency
have provided strong support for the concept of “safe tar-
gets”; i.e., that parasites persist in cells with intrinsic defects
in immune-potentiated killing mechanisms.
In the present studies, the factors controlling 
 
L. major
 
persistence and reactivation after clinical cure have been
examined in a model of latency established either as a con-
sequence of natural sand fly challenge or an infection
model that combines two main aspects of natural challenge,
low parasite dose (100 metacyclic promastigotes) and inoc-
ulation into skin (ear dermis) (13). The studies demonstrate
that in addition to CD4
 
 
 
 T cells, CD8
 
 
 
 T cells are needed
to maintain control of the parasite in the chronic site. More
importantly, the results reveal a requirement for IL-10 in
parasite persistence, and demonstrate a remarkable thera-
peutic effect of anti–IL-10 receptor Ab in eliminating
chronic infection and the risk of reactivation disease.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice, C57BL/10, C57BL/6 IL-4
 
 
 
/
 
 
 
,
C57BL/10 IL-10
 
 
 
/
 
 
 
, and C57BL/6 IL-10/4
 
 
 
/
 
 
 
 double cyto-
kine-deficient mice (14) were obtained from Taconic Farms and
were between 6 and 8 wk of age at the start of each study. For
some experiments, C57BL/6 mice were purchased from the Di-
vision of Cancer Treatment, National Cancer Institute (Freder-
ick, MD). All mice were maintained in the National Institute of
Allergy and Infectious Diseases animal care facility under specific
pathogen-free conditions.
 
Parasite Preparation, Intradermal Inoculation, and Estimation of Par-
asitic Load. Leishmania major
 
 clone V1 (MHOM/IL/80/Friedlin)
was cultured as described previously (15). Infective stage metacy-
clic promastigotes of 
 
L. major
 
 were isolated from stationary cul-
tures (4–5 d old) by negative selection using peanut agglutinin.
100 metacyclic promastigotes were inoculated intradermally into
the ear dermis (both ears) using a 27 1/2 G needle in a volume of
 
 
 
5 
 
 
 
l. The evolution of the lesion was monitored by measuring
the diameter of the induration of the ear lesion with a direct read-
ing vernier caliper (Thomas). Parasite titrations in biphasic media
for estimation of parasite loads were performed as described pre-
viously (16). The plating efficiency of 
 
L. major
 
 in this limiting di-
lution assay ranges between 50 and 150% (17).
 
Ab Treatment of Healed C57Bl/6 Mice.
 
Clinically cured ani-
mals were injected intraperitoneally once a week for a period of 2
to 4 wk with 1 mg of monoclonal anti-CD4 (GK1.5), anti-CD8
(2.43), anti–IFN-
 
 
 
 (XMG-6), or isotype control (GL113, rat
IgG1). For inhibition of IL-10, mice were inoculated intraperito-
neally every 3 d with 0.5 mg monoclonal anti–IL-10 receptor
mAb (DNAX [18]) or isotype control for a period of 2 wk. All of
the mAbs were prepared by ammonium sulfate precipitation of
ascites fluid and subsequent dialysis against PBS.
 
LN Cell Preparation and Culture.
 
The submandibular ear skin
draining LNs were recovered and mechanically dissociated using
a pellet pestle. The cell viability was assessed by trypan blue ex-
clusion. For measurement of in vitro cytokine production, single-
cell suspensions of LNs were pooled from four to five animals,
diluted to 4 
 
 
 
 10
 
6
 
 cells/ml, and dispensed into 96-well plates
without antigen, or with soluble 
 
L. major
 
 antigen (SLA; 25 
 
 
 
g/
ml) or Con A (2 
 
 
 
g/ml) in 100 
 
 
 
l of complete RPMI containing
 
 
 
-mercaptoethanol. Cultures were incubated at 37
 
 
 
C in 5%
CO
 
2
 
. Supernatant fluids were harvested at 48–72 h and assayed
by ELISA for IFN-
 
 
 
 as described previously (11) and for IL-10
using Endogen kit (Endogen) according to the manufacturer’s in-
structions.
 
Analysis of Lymphocytes in the Skin.
 
To characterize leuko-
cytes present in the inoculation site, the ears were collected and
the ventral and dorsal dermal sheets separated and incubated 1 h
at 37
 
 
 
C, dermal side down on RPMI 1640, NaHCO
 
3
 
, penicillin/
streptomycin/gentamycin, containing 0.28 Wunsch units/ml of
liberase blendzyme CI (Roche). The dermal sheets from three to
five animals were pooled, and processed in the presence of 0.05%
DNase (Sigma-Aldrich) using Medimachine (BD PharMingen)
according to the manufacturer’s instructions. After processing,
cell viability was assessed by trypan blue exclusion and the cells
were filtered trough a 50-
 
 
 
m filter and washed before activation
and/or immunolabeling.
 
In Vitro Restimulation, Immunolabeling, and Flow Cytometry.
 
Unfractionated LN cells or dermal cells were incubated for 4 h in
the presence of 10 
 
 
 
g/ml of anti-CD28 (37.51; BD PharMin-
gen), 5 ng/ml IL-2 (Endogen), and 25 
 
 
 
g/ml of SLA or alterna-
tively with fetal skin–derived dendritic cells (FSDDCs), prepared
from C57BL/6 mice and infected as described previously (19)
followed by a 2-h incubation with Brefeldin A (Sigma-Aldrich).
Prior to staining, LN or dermal cells were incubated with an anti-
Fc
 
 
 
III/II receptor (BD PharMingen) mAb and 10% normal
mouse serum (NMS) in PBS containing 0.1% BSA, 0.01% NaN
 
3
 
.
The lymphocytes were identified by characteristic size (forward
scatter [FSC]) and granularity (side scatter [SSC]), in combination
with anti-TCR 
 
 
 
 chain (H57–597, FITC conjugated; BD
PharMingen) and anti-CD4 (H129.19) or CD8 (53–6.7) (Cy-
Chrome or allophycocyanin [APC] conjugated; BD PharMingen)
surface staining followed or not by a permeabilization step and
staining with anti–IFN-
 
 
 
 (XNG1.2; BD PharMingen) or/and
anti–IL-10 (JES5–16E3). The isotype controls used were rat
IgG2b (A95–1; BD PharMingen), rat IgG2a (R35–95; BD
PharMingen), and hamster IgG, group2 (Ha4/8; BD PharMin-
gen). For each sample, between 200,000 and 400,000 cells
were  analyzed. The data were collected and analyzed using
CELLQuest™ software and a FACSCalibur™ flow cytometer
(Becton Dickinson).
 
Natural Sand Fly Challenge.
 
2–4-d-old 
 
Phlebotomus papatasi
 
females were obtained from a colony initiated from field speci-
mens collected in Saudi Arabia. Flies were infected by artificial
feeding on a chick membrane at 37
 
 
 
C as described previously
(20). 15 d after the blood meal, 10 infected flies per ear were al-
lowed to feed for 2–3 h in the dark, after which time each fly was
examined for blood. The ability of infected ears to provide a
source of parasites for sand fly infections was investigated using
2–4-d-old uninfected flies that were allowed to feed on the ears
of chronically infected mice. Blood fed flies were separated, pro-
vided a 50% sucrose solution and water, and their midguts were
dissected 48 h later and examined microscopically for the pres-
ence of promastigotes.
 
Results
 
Persistence of L. major in the Skin after Healing in Resistant
Mice.
 
After inoculation of 100 metacyclic promastigotes
of 
 
L. major
 
 into the ear dermis of C57BL/6 mice, the para-
site number increased in the absence of overt pathology for
a period of 4–5 wk (Fig. 1 A). Killing and/or clearance of 
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dermal parasites occurred after the 5th week, and was asso-
ciated with the development of a small lesion that healed
spontaneously 8–10 wk after infection. Resolution of the
dermal lesion was associated with 
 
 
 
99% reduction in the
number of parasites in the skin. Nonetheless, sterile immu-
nity was not achieved in the inoculation site (6,000 para-
sites/ear 24 wk after challenge; Fig. 1 A) or in the draining
LN (460 
 
 
 
 320 parasites/node, data not shown). This low
level of infection persisted for the life of the animal (
 
 
 
1
yr). When ears harboring latent infections (6 mo) were ex-
posed to the bites of a natural vector, 
 
Phlebotomus papatasi
 
,
75% (6 of 8 ears) transmitted parasites to these flies (data
not shown). Thus the persistence of even low numbers of
parasites in the skin after healing was formally shown to
maintain the host as a long term reservoir of infection.
 
Both CD4
 
 
 
 and CD8
 
 
 
 T Cells Are Required to Maintain
Immunity in the Site.
 
Reactivation of latent 
 
L. major
 
 infec-
tion has been previously shown to occur after in vivo treat-
ment using Abs against CD4, IFN-
 
 
 
, or IL-12, as well as
iNOS inhibitors (9, 10, 21, 22). The effect of in vivo de-
pletion of CD8
 
 
 
 T cells has not been reported, although
the maintenance of iNOS activity was found to be CD4
dependent and CD8 independent (9). 3 mo after healing of
their dermal lesions, C57Bl/6 mice were treated with anti-
CD4 or anti-CD8 Abs. Control-treated mice maintained
between 10 and 1,000 parasites in the primary site of the
infection (Fig. 1 B). At 2.5 wk after CD8 depletion, the
number of parasites increased dramatically (10,000-fold),
whereas the increase in the CD4-depleted mice was more
modest at this time (100-fold). At 4.5 wk, both groups har-
bored a 3–4 log fold increase in the number of parasites in
the chronic site compared with control treated mice. Both
groups of mice reactivated their dermal pathology, as early
as 1 wk after treatment for the anti-CD8 and at 2 wk for
the anti-CD4–treated mice (data not shown). The require-
ment for both T cell subsets in maintaining immune pres-
sure on the parasite in the chronic site was associated with a
high number of CD4
 
 
 
 T cells (4.3 
 
 
 
 10
 
5
 
 cells/ear) and
CD8
 
 
 
 T cells (5.7 
 
 
 
 10
 
4
 
 cells/ear) recovered from the in-
fected dermis compared with steady-state ears (1.2 
 
 
 
 10
 
4
 
CD4
 
 
 
 T cells and no CD8
 
 
 
 T cells) (Fig. 1 C).
 
IL-10–deficient Mice Achieve Sterile Cure.
 
Both IL-4 and
IL-10 have been shown to play a role in promoting non-
healing 
 
L. major
 
 infections in BALB/c mice (23–25). The
role of these cytokines in favoring the long term persistence
of the parasite after healing in resistant mice was investi-
gated by comparing acute and chronic stage infections in
C57BL/6 and C57BL/10 wild-type and in IL-10, IL-4,
and IL-10/4 knockout (KO) mice. The immunodeficient
mice developed self-healing cutaneous lesions comparable
to their respective wild-type controls (Fig. 2 A). The IL-
10/4 KO mice required 3–4 wk longer for lesion resolu-
tion, likely due to the impaired ability of these mice to
downregulate type 1–mediated inflammatory reactions
(14). While all of the IL-10 and IL-10/4 KO mice showed
clear evidence of established infections at 6 wk after chal-
lenge, they had a 100–500-fold reduction in the number of
parasites in the skin and LN compared with their wild-type
Figure 1. Chronic phase L. major infection in C57BL/6 mice. (A)
Number of parasites per ear ( ) and diameter of induration ( ) after in-
tradermal inoculation of 100 L. major metacyclics in the ear of C57BL/6
mice. Values represent mean induration in mm   SD, 3–5 mice per
group, and geometric mean parasite number per ear   SD, 5 mice and 10
ears per group. (B) Number of parasites in the ear 5 mo after intradermal
inoculation of 100 L.major metacyclics and treated for 2.5 ( ) or 4.5 ( )
wk with anti-CD4, anti-CD8, or isotype control before titration. Bars
represent geometric mean parasite number per ear, four mice and eight
ears per group. The experiment is representative of three separate experi-
ments. (C) Dot plots of TCR  CD4  and TCR  CD8  cells present in
the ear dermis 6 mo after challenge. The dermal sheets of four mice were
pooled. The data shown are from a single experiment, representative of
three separate experiments. 
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controls (Fig. 2 B). At 9.5 wk after infection, when low
level, chronic stage infections had been established in the
wild-type mice, the IL-4–deficient mice maintained an
even higher number of parasites in the site. In contrast,
both the IL-10 and IL-10/4 KO mice completely cleared
the parasite from the primary site of the infection and from
the draining LN (Fig. 2 C). The complete clearance
achieved in the IL-10–deficient groups was not related to
the lower levels of peak parasitemias established in these
mice, since in a separate experiment, when parasites loads
were determined at 4 wk after infection before the onset of
immunity, the numbers in the IL-10 KO and C57BL/10
wild-type mice were comparable (1.9 
 
  
 
10
 
5 
 
 
 
 2.3 
 
  
 
10
 
4
 
versus 3.0 
 
  
 
10
 
5
 
   1.9   104 parasites/ear).
To substantiate that acquired immunity in the IL-10 or
IL-10/4 KO mice resulted in sterile cure, the healed mice
were treated with anti–IFN-  in order to reveal the pres-
ence of residual organisms. 3 wk after IFN-  neutraliza-
Figure 2. IL-10 and IL-10/4 KO mice achieve sterile immunity. (A) Diameter of induration after intradermal inoculation of 100 L.major metacyclics
in C57BL/6 ( ), C57BL10 ( ), IL-10 /  ( ), IL-4 /  ( ), and IL-10/4 /  ( ) mice. Values represent mean induration in mm   SD, 12–9 mice and
24–18 ears per group. (B) Number of parasites 6 wk, and (C) and 9.5 wk after challenge in the dermal site ( ) or in the LN ( ), three mice and six ears
per group. The experiment is representative of four separate experiments. WT, wild-type. (D) Number of parasites in the dermis or (E) in the draining
LN 6 mo after challenge and treated with anti–IFN-  or isotype control for 2.5 wk before parasite titration; three mice, six ears or LNs per group. The
experiment is representative of three separate experiments.1501 Belkaid et al.
tion, the number of dermal and LN parasites increased by
20-fold and 100-fold in the wild-type and IL-4 KO mice,
respectively (Fig. 2, D and E). In the IL-10 and IL-10/4
KO mice, the anti–IFN-  treatment failed to reveal the
presence of parasites in 11 of 12 lesions (Fig. 2 D). All of
the draining LNs remained negative for parasites (Fig. 2 E).
The persistence of L. major in the skin after healing of
dermal lesions resulting from sand fly challenge has re-
cently been demonstrated (20). To confirm the role of IL-
10 in this natural infection model, the ears of C57BL/10
and IL-10 KO mice were exposed on each ear to the bites
of 10 P. papatasi sand flies harboring mature L. major infec-
tions. 12/14 ears in the wild-type mice and 11/12 ears in
the IL-10 KO mice developed lesions. The lesions ap-
peared earlier and progressed more rapidly in the IL-10
KO mice, but resolved rapidly by 4 wk in both groups of
mice (Fig. 3 A). At 9 wk after infection, the healed ears
from all of the wild-type mice harbored between 102 and
2   106 parasites per ear (Fig. 3 B). The two ears that never
developed lesions were negative for parasites. In addition,
the pooled draining nodes from each of the wild-type mice
harbored an average of 5   103 parasites per node. In the
IL-10 KO mice, 4 of 6 mice and 8 of 12 ears were nega-
tive for L. major, and the 4 positive ears harbored only low
numbers of parasites ( 200). The ear draining nodes,
pooled for each mouse, were negative for parasites in 4 of
6 mice (Fig. 3 B).
Treatment Using Anti–IL-10 Receptor Ab Promotes Sterile
Cure in C57Bl/6 Mice. To confirm the role of IL-10 for
the maintenance of L. major in the wild-type mice, and to
investigate the effects of IL-10 neutralization initiated after
latency has already been established, C57BL/6 mice were
treated at 24 wk after infection with anti–IL-10R mAb.
Control treated mice harbored an average of 3,100 para-
sites in the dermis and 520 parasites in the draining LN
(Fig. 4). 2 wk after treatment using anti–IL-10R mAb, 10
of 13 mice (20 of 26 ears and 22 of 26 LNs) were negative
for parasites.
Analysis of IFN-  and IL-10 Production by T Cells within
the Dermis and Draining LN. The IL-10 and IFN-  re-
sponse of LN cells to SLA was monitored after low dose
inoculation into the skin for a period of 24 wk (Fig. 5).
Low levels of IFN-  were detectable by 3 wk and its pro-
duction followed the evolution of the lesion, with a peak at
6–7 wk and its maintenance at high levels during the
chronic stage (11–14 ng/ml). IL-10 was also detectable as
early as 3 wk, peaked during the acute stage of the infec-
tion at 6 wk (9.1 ng/ml), and remained detectable
throughout the chronic stage (3.6 ng/ml 24 wk after chal-
lenge). LN cells from IL-10 or IL-10/4 KO mice produced
higher levels of IFN-  in response to SLA during the acute
stage of the infection compared with the wild-type mice or
to IL-4 KO mice (Table I). 15 wk after challenge, when
parasites could no longer be detected, neither the IL-10
nor 10/4 KO mice produced significant levels of IFN- ,
while its production remained relatively high in the wild-
type and IL-4 KO mice.
To define the contribution of CD4  and CD8  T lym-
phocytes to the production of IL-10 and IFN- , LN cells
Figure 3. Natural infection of IL-10 KO mice. (A) The course of in-
fection after transmission of L. major by bite of P. papatasi in C57BL/10
( ) and C57BL/10 IL-10 /  mice ( ); 6 to 8 mice, 12 to 16 ears per
time point. The value shown at each time point are the sum of the le-
sion’s diameter   1 SD. (B) Parasite number in the ear ( ) and draining
LN ( ), 9 wk after bite. The two draining LNs from individual mice
were pooled. The bar represents geometric mean parasite number; 6–8
LNs and 12–16 ears per group.
Figure 4. Anti–IL-10 receptor treatment of chronically infected mice.
Number of parasites in the dermis ( ) or LN ( ) of C57BL/6 mice
treated beginning at 7 mo after infection with anti–IL-10R mAb or iso-
type control for 2 wk before titration. Bars represent the geometric mean
of the parasite number per ear, 13 mice and 26 ears or draining LNs per
group. The data represent a pool of three separate experiments.1502 Role of IL-10 in Chronic Leishmania major Infection
and cells extracted from the chronic dermal site were re-
stimulated in vitro with SLA, anti-CD28, and IL-2, or al-
ternatively with L. major infected FSDDCs, and analyzed
by flow cytometry. While both conditions efficiently acti-
vated CD4  T cells for cytokine production, intracellular
staining of cytokines in CD8  T was only observed after
restimulation using infected FSDDCs. Under these condi-
tions, 29% of the CD4  T cells recovered from the skin
produced IFN-  and 7.1% produced IL-10, while 2.7% of
the CD8  T cells produced IFN-  and 3.1% produced IL-
10 (Fig. 6 A). The majority of the dermal CD4  T cells
that produced IL-10 also produced IFN-  (Fig. 6 B). Using
infected FSDDCs for in vitro restimulation of LN cells,
1.2% of the CD4  T cells produced only IL-10, 1.1% pro-
duced only IFN- , and 0.9% produced both cytokines
(Fig. 6 B). CD8  T cells recovered from LN were also able
to release IL-10 or IFN-  (0.6% and 5% of the CD8  T
cells, respectively). LN and dermal cells from naive mice
stimulated under the same conditions were negative for ei-
ther cytokine (data not shown).
The effect of IL-10 neutralization on cytokine produc-
tion was analyzed after 1 and 2 wk of Ab treatment. 1 wk
after treatment, the level of IFN-  secreted by LN cells in
response to SLA was modestly increased compared with
control treated, chronically infected mice (18.2   3.2 vs.
12   2.3 ng/ml). 2 wk after treatment the level of IFN- 
was lower in the anti–IL-10R-treated mice compared with
the chronic control mice (9.1 ng/ml   1.2 vs. 14.5   3.1
ng/ml). 1 wk after anti–IL-10R treatment the numbers of
CD4  and CD8  T cells recovered from the chronic site
were dramatically reduced by 86 and 97%, respectively
(Fig. 6 C). Of the CD4  T cells remaining in the site, 5%
still produced IFN- , whereas IL-10–producing cells were
no longer detected.
Discussion
Many pathogens are capable of long term persistence in
their host after clinical cure, creating the risk of disease re-
activation when the host/parasite equilibrium is disturbed.
In humans, most Leishmania species are known to establish
latency, and their reactivation can produce severe clinical
outcomes, including visceral, cutaneous, or mucocutane-
ous forms of disease. In the present studies, low dose, intra-
dermal inoculation of L. major in resistant mice, as well as
actual sand fly challenge, were used to investigate the fac-
tors favoring parasite persistence and reactivation in a
model that more accurately reflects the conditions of la-
tency associated with natural infection. The results confirm
that the number of parasites in the skin during latency are
sufficient to maintain the immune host as a long term res-
ervoir of infection for vector sand flies. The results also ex-
tend prior observations regarding the immune mechanisms
involved in maintaining host control over parasite replica-
tion in the skin, indicating that in addition to CD4  T
cells, CD8  T cells are required. Most importantly, the re-
sults clearly demonstrate that IL-10 is required for L. major
persistence, as evidenced by the finding that IL-10–defi-
cient mice or wild-type mice treated during the chronic
stage with anti–IL-10 receptor Ab, achieved sterile immu-
nity in the skin and draining LNs, and were no longer at
risk of disease reactivation.
A role for IL-10 in promoting susceptibility to L. major
infections in the mouse remained unsupported (26, 27) un-
til a recent report indicating that resistant mice expressing
an IL-10 transgene under the control of the MHC II Ea
promoter were more susceptible (24), and conversely, that
BALB/c IL-10 KO mice were more resistant, though they
still harbored high numbers of parasites (25). In each case,
over production of IL-10 was concluded to promote non-
healing, progressive disease. The present model describes a
role for IL-10 that functions in the context of a powerful
Th1 response that promotes healing and effectively elimi-
nates the majority of parasites from the host, and that may
reflect a homeostatic mechanism to dampen the potentially
harmful effects of this immune response on the host. It is
important to note that while the high level of IL-4 induced
by L. major is clearly a codeterminant of nonhealing infec-
tions in BALB/c mice (28), IL-4 appears to play no role in
promoting parasite persistence in healed, resistant mice,
Figure 5. Antigen-specific cytokine release by LN cells. (A) LN cells
from C57BL/6 mice were pooled at each time point from four mice and
eight LNs, stimulated in vitro with SLA, and the supernatants were col-
lected at 48 h for determination of IL-10 ( ) and IFN-  ( ). Values repre-
sent the mean cytokine concentration of four separate experiments   1 SD.
Table I. IFN-  Production by LN Cells from
Immunodeficient Mice
C57BL/6 C57BL/10 IL-10 /  IL-4 /  IL-10/4 / 
6 wk 21   5.5a 48   6.2 81   5.1 42   2 79   8.2
15 wk 34   2.1 26   1.1 0 84   4.5 3   1.1
aMean cytokine concentration 6   SD (ng/ml) produced by draining
LN cells (four mice, eight LNs per group) assayed 72 h after stimulation
with 25  g/ml SLA.1503 Belkaid et al.
since chronic infection became just as well established in
the IL-4 KO as in the wild-type mice.
The function of IL-10 as a suppressive or deactivating
cytokine is well described; in vitro, it has been shown to
inhibit antigen presentation (29), antigen-specific T cell
proliferation and type 1 cytokine production (30–32), and
to render macrophages refractory to activation by IFN- 
for intracellular killing (25, 33, 34). The sterile immunity
achieved in the IL-10 KO and IL-10/4 KO mice might be
explained, at least in part, by the fact that they developed a
Figure 6. Single cell analysis
of cytokine production by der-
mal and LN T cells. (A) 7 mo af-
ter infection, dermal leukocytes
were pooled from four mice
(eight ears), restimulated with L.
major infected FSDDCs, and
stained for detection of surface
markers and intracellular cyto-
kines. Cells were gated on
TCR   cells. The numbers rep-
resent the percentage of CD4 
or CD8  cells also positive for
IL-10 or IFN- . (B) Dermal or
LN cells from mice 7 mo after
infection were gated on
CD4 TCR   or CD8 TCR  
cells. The numbers represent the
percentage of gated cells positive
for IL-10, IFN- , or both cyto-
kines. The data shown in A and
B are from a single experiment,
representative of five separate ex-
periment. (C) 6 mo after infec-
tion, C57Bl/6 mice were treated
for 1 wk with anti–IL-10R mAb
or isotype control and dermal
cells from four mice (eight ears)
per group were pooled, restimu-
lated with anti-CD28, IL-2, and
SLA, and stained. Cells were
gated on TCR   cells. Num-
bers shown are the absolute
number of CD4  or CD8  cells
per ear positive or negative for
IL-10 or IFN- . The data are
from a single experiment that is
representative of two separate
experiments.1504 Role of IL-10 in Chronic Leishmania major Infection
more potent TH1 response during the acute stage, consis-
tent with prior observations regarding IL-10 KO mice (35).
Wild-type mice treated with anti IL-10 receptor mAb also
showed a transient upregulation of IFN- , consistent with
the use of this reagent as an adjuvant to prime TH1 cells in
response to soluble antigen (36). While in this study the
anti–IL-10 receptor mAb only worked if LPS was also
present to activate the innate response, in the chronic in-
fection model, the presence of L. major amastigotes (37)
and/or activated T cells expressing CD40L (38) may have
provided a sufficient stimulus, in conjunction with IL-10
neutralization, to appropriately activate DCs for TH1 up-
regulation. On the other hand, after 2 wk of treatment with
anti–IL-10 receptor Ab, the amount of IFN-  secreted by
LN cells was lower than control treated mice and the num-
ber of T cells producing IFN-  in the site was dramatically
reduced. The level of IFN-  produced by wild-type mice
during the chronic stage remained in any case high, even
when IL-10 was present. Thus, an enhanced TH1 response
seems less a predictor of sterile cure than is the absence of
IL-10 or IL-10 receptor signaling. This is consistent with
the observations in the IL-10 transgenic B6 mice, which
were converted to an L. major susceptible phenotype de-
spite the fact that they were still able to mount a strong
Leishmania-specific TH1 response (24). The data favor a
role for IL-10 in conditioning the host cells so that they be-
come poorly responsive to even high levels of IFN-  for
intracellular killing. Persistence does not appear to be ex-
plained by the “safe target” model (12), as regardless of the
nature of the cells harboring the parasites, the absence of
IL-10 revealed an ability of these cells to be activated for ef-
fective killing. These mechanisms are not mutually exclu-
sive, however, as it is possible that were it not for the up-
take of parasites by cells that are poorly responsive to IFN- 
and/or highly sensitive to deactivation by IL-10, then the
infections might be cleared even in the presence of IL-10.
In our own study, we found a high proportion of DC-like
cells harboring Leishmania in the skin during the chronic
phase. While the capacity of DC to release NO and trigger
the killing of the parasite have differed depending on the
source of DCs and the activation signals involved (9, 39),
our data suggest that the equilibrium of the chronic site is
maintained by infected DCs and macrophages that remain
responsive to both IFN-  and IL-10.
CD4  T cells appear to be the main producers of IFN- 
and IL-10 in the dermis, although CD8  T cells were also
able to produce either cytokine when the in vitro restimu-
lation conditions were altered to include infected FSDDCs.
In the draining node, both subsets were able to produce
IFN-  or IL-10. Interestingly, the majority of the CD4  T
cells in the dermis and a smaller subset of CD4  T cells in
the draining node were able to produce both IL-10 and
IFN- . CD4  T cells with a similar cytokine profile,
termed Tr-1 cells, have recently been shown to play an es-
sential role in the maintenance of peripheral tolerance (40–
43). Their role in chronic infection has not been demon-
strated in experimental models, but is suggested by the
presence of IFN- /IL-10 secreting T cells that are gener-
ated in response to persistent infections, including tubercu-
losis (44), malaria (45), and B. burgdorferi infection in hu-
mans (46). In the later example, the generation of these
cells was IL-12 dependent, consistent with the ability of IL-
12 to prime human CD4  and CD8  T cell clones for pro-
duction of both IFN-  and IL-10 (47). Non T cell sources
of IL-10 need to be considered; Leishmania are known, for
example, to efficiently prime host macrophages for IL-10
production in response to second activation signals involv-
ing IFN-  or Fc  receptor ligation (15, 25). The relative
contribution of these various cells to the amount or local-
ization of IL-10 required to maintain parasite survival is not
apparent from our studies. Any role that the IL-10 produc-
ing CD4  and/or CD8  T cells play in promoting parasite
survival that might have been discerned by depletion ex-
periments was obscured by their essential role in maintain-
ing host immunity. As reported previously (8) and con-
firmed here, anti-CD4 treatment during latency resulted in
disease reactivation. Our finding that CD8  cells are also
necessary to maintain immune pressure in the chronic der-
mal site is consistent with prior observation in CBA mice
with healed footpad lesions that were reactivated when the
mice were treated with anti-CD8 Abs at the time of sec-
ondary high dose challenge in a different site (48). The re-
quirement for both subsets is presumably related to the cu-
mulative level and/or localization of IFN-  that they
release. Alternatively, as the high amount of IFN-  pro-
duced by CD4  T cells alone would seem sufficient, CD8 
cells might contribute additional effector activities to im-
mune maintenance (e.g., cytotoxicity, chemokine release).
In humans, the involvement of IL-10 in Leishmania per-
sistence and in a reactivation process is indicated by the find-
ing that high levels of plasma IL-10 and the expression of
IL-10 by keratinocytes was predictive of the development of
PKDL (49). The clinical findings that are most relevant to
the present studies are those indicating that even in cured
cases of visceral or localized cutaneous disease, IL-10 contin-
ues to be produced along with IFN-  (50–53), and may ex-
plain the failure of these individuals to achieve sterile cure.
Our finding that healed mice, treated for a short period of
time during latency with anti–IL-10 receptor Abs, achieved
complete clearance of parasites from the skin and draining
nodes, suggests a therapeutic approach that either alone or in
conjunction with standard treatments might promote sterile
immunity, thereby reducing the pool of infection reservoirs
and eliminating the risk of reactivation disease.
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